{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-24-000089","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2024-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.873886+00:00","generated_at":"2026-05-29T23:52:12.572475+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Barinthus/Arbutus HBV data: 23% HBsAg loss with nivolumab; 2 functional cures in Phase 2b","bullets":["IM-PROVE II Group C: 23% (3/13) on imdusiran + VTP-300 + low-dose nivolumab achieved HBsAg loss by Week 48.","HBV003: 8 participants achieved HBsAg loss; 2 met functional cure criteria; 2 seroconverted to HBsAb.","In HBV003, 66% (6/9) who discontinued NUCs remained off therapy >6 months, 2 meeting functional cure.","Both regimens were generally well tolerated with no treatment-related SAEs reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-24-000089","json":"https://secwatch.observer/filing/0001828185-24-000089.json","markdown":"https://secwatch.observer/filing/0001828185-24-000089.md","text":"https://secwatch.observer/filing/0001828185-24-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/0001828185-24-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818524000089/brns-20241115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T23:52:12.572475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}